Research programme: influenza A/B inhibitor therapeutics - Cocrystal Phama/Merck
Alternative Names: Influenza A/B inhibitors - Cocrystal Phama/MerckLatest Information Update: 01 Mar 2024
Price :
$50 *
At a glance
- Originator Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 29 Feb 2024 Preclinical development is ongoing USA in Influenza A virus infections and Influenza B virus infections (Cocrystal pharma pipeline, February 2024)
- 15 Dec 2023 Cocrystal Pharma terminates licensing and collaboration agreement with Merck for the development and commercialisation of Influenza A/B antiviral agents
- 28 May 2023 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in USA